Blood-based predictive biomarkers for overall survival (OS) in patients (pts) receiving the immunotherapy sipuleucel-T (sip-T).
Oh W, Kandadi H, Sheikh N, Galsky M. Blood-based predictive biomarkers for overall survival (OS) in patients (pts) receiving the immunotherapy sipuleucel-T (sip-T). Journal Of Clinical Oncology 2017, 35: 36-36. DOI: 10.1200/jco.2017.35.7_suppl.36.Peer-Reviewed Original ResearchMinimally symptomatic metastatic castration-resistant prostate cancerOverall survivalPeripheral bloodSymptomatic metastatic castration-resistant prostate cancerMetastatic castration-resistant prostate cancerBaseline prostate-specific antigen levelBlood-based predictive biomarkersPredictive of OS benefitProstate-specific antigen levelCastration-resistant prostate cancerMultivariate Cox proportional hazards regression modelsImmunotherapy sipuleucel-TPB mononuclear cellsAssociated with OSPredictive of OSCox proportional hazards regression modelsFDA-approved immunotherapyProportional hazards regression modelsGene expressionHazards regression modelsGene expression signaturesAssociation of gene expressionMedian OSSipuleucel-TOS benefit
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply